Trial Profile

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Primary endpoint (Radiographic Progression Free Survival (rPFS)) has not been met.
04 Jun 2024 Primary results (n=393) of CYCLONE 2 study presented at the 60th Annual Meeting of the American Society of Clinical Oncology
23 May 2024 According to an Eli Lilly and Company media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 - June 4 in Chicago.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com